EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 142 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer (EOC) MOST POPULAR Active Surveillance for Low-Risk Prostate Cancer Continues to Rise June 23, 2022 Becoming My Own Advocate While Living With a Rare Cancer: A... April 27, 2023 “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain... June 8, 2021 Cell Phone Use May Increase Risk of Breast and Thyroid Cancer,... January 7, 2021 Load more HOT NEWS Breast cancer surgery: ‘I’m proud of the tattoos inked across my... A new approach to cancer immunotherapy ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland ESMO Releases New Patient Guide in Hepatocellular Carcinoma
